JP2005511721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511721A5 JP2005511721A5 JP2003550783A JP2003550783A JP2005511721A5 JP 2005511721 A5 JP2005511721 A5 JP 2005511721A5 JP 2003550783 A JP2003550783 A JP 2003550783A JP 2003550783 A JP2003550783 A JP 2003550783A JP 2005511721 A5 JP2005511721 A5 JP 2005511721A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- present
- active ingredient
- treatment
- carcinoid syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 5
- 206010007270 Carcinoid syndrome Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 3
- 239000003793 antidiarrheal agent Substances 0.000 description 3
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 description 3
- 239000008896 Opium Substances 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 229960001027 opium Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 102000002419 Motilin Human genes 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000008414 paregoric Substances 0.000 description 1
- 229940069533 paregoric Drugs 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34216701P | 2001-12-13 | 2001-12-13 | |
| US41599002P | 2002-10-04 | 2002-10-04 | |
| PCT/EP2002/014162 WO2003049734A1 (en) | 2001-12-13 | 2002-12-12 | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511721A JP2005511721A (ja) | 2005-04-28 |
| JP2005511721A5 true JP2005511721A5 (https=) | 2006-01-26 |
| JP4672257B2 JP4672257B2 (ja) | 2011-04-20 |
Family
ID=26992855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550783A Expired - Fee Related JP4672257B2 (ja) | 2001-12-13 | 2002-12-12 | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20050020647A1 (https=) |
| EP (1) | EP1463504B1 (https=) |
| JP (1) | JP4672257B2 (https=) |
| KR (1) | KR101010767B1 (https=) |
| CN (1) | CN1602192A (https=) |
| AT (1) | ATE330602T1 (https=) |
| BR (1) | BR0214917A (https=) |
| CA (1) | CA2468994A1 (https=) |
| CY (1) | CY1105459T1 (https=) |
| DE (1) | DE60212710T2 (https=) |
| DK (1) | DK1463504T3 (https=) |
| ES (1) | ES2266610T3 (https=) |
| HU (1) | HUP0402537A3 (https=) |
| IL (1) | IL162166A0 (https=) |
| MX (1) | MXPA04005712A (https=) |
| NO (1) | NO332773B1 (https=) |
| NZ (1) | NZ533378A (https=) |
| PL (1) | PL209147B1 (https=) |
| PT (1) | PT1463504E (https=) |
| RU (1) | RU2341261C2 (https=) |
| TW (1) | TWI287986B (https=) |
| WO (1) | WO2003049734A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2003235761A1 (en) * | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| CA2499682A1 (en) * | 2002-10-09 | 2004-04-22 | Kosan Biosciences, Inc. | Epo d + 5-fu/gemcitabine |
| AU2004268377B2 (en) * | 2003-09-02 | 2008-06-26 | Novartis Ag | Cancer treatment with epothilones |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| HUE071943T2 (hu) | 2015-02-03 | 2025-10-28 | Amryt Endo Inc | Akromegália kezelése oktreotid orális alkalmazásával |
| RU2633266C2 (ru) * | 2015-07-02 | 2017-10-11 | Рауф Ашрафович Ашрафов | Способ моделирования карциноидного синдрома |
| JP2025508846A (ja) * | 2022-02-25 | 2025-04-10 | アムリット・エンドゥ・インコーポレイテッド | 疾患の治療のための経口オクトレオチド |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356270A (en) * | 1977-11-08 | 1982-10-26 | Genentech, Inc. | Recombinant DNA cloning vehicle |
| US4318477A (en) * | 1980-09-22 | 1982-03-09 | Kerpe Stase Z | Pharmaceutical package |
| US5753616A (en) * | 1986-11-10 | 1998-05-19 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| DE3845000C2 (de) * | 1987-07-10 | 1998-11-19 | Novartis Ag | Anwendung von Octreotid zur Behandlung von Brustkrebs |
| KR20000015944A (ko) * | 1996-05-24 | 2000-03-15 | 팜 윌리암 엔. | 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법 |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| DK1367057T3 (da) * | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
-
2002
- 2002-12-11 TW TW091135843A patent/TWI287986B/zh not_active IP Right Cessation
- 2002-12-12 ES ES02790487T patent/ES2266610T3/es not_active Expired - Lifetime
- 2002-12-12 KR KR1020047009001A patent/KR101010767B1/ko not_active Expired - Fee Related
- 2002-12-12 EP EP02790487A patent/EP1463504B1/en not_active Expired - Lifetime
- 2002-12-12 DK DK02790487T patent/DK1463504T3/da active
- 2002-12-12 MX MXPA04005712A patent/MXPA04005712A/es active IP Right Grant
- 2002-12-12 AT AT02790487T patent/ATE330602T1/de active
- 2002-12-12 CN CNA028248341A patent/CN1602192A/zh active Pending
- 2002-12-12 US US10/498,069 patent/US20050020647A1/en not_active Abandoned
- 2002-12-12 DE DE60212710T patent/DE60212710T2/de not_active Expired - Lifetime
- 2002-12-12 JP JP2003550783A patent/JP4672257B2/ja not_active Expired - Fee Related
- 2002-12-12 PT PT02790487T patent/PT1463504E/pt unknown
- 2002-12-12 CA CA002468994A patent/CA2468994A1/en not_active Abandoned
- 2002-12-12 PL PL369141A patent/PL209147B1/pl not_active IP Right Cessation
- 2002-12-12 RU RU2004121687/15A patent/RU2341261C2/ru not_active IP Right Cessation
- 2002-12-12 WO PCT/EP2002/014162 patent/WO2003049734A1/en not_active Ceased
- 2002-12-12 HU HU0402537A patent/HUP0402537A3/hu unknown
- 2002-12-12 BR BR0214917-6A patent/BR0214917A/pt not_active IP Right Cessation
- 2002-12-12 IL IL16216602A patent/IL162166A0/xx unknown
- 2002-12-12 NZ NZ533378A patent/NZ533378A/xx not_active IP Right Cessation
-
2004
- 2004-07-05 NO NO20042832A patent/NO332773B1/no not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/451,286 patent/US20060229345A1/en not_active Abandoned
- 2006-09-07 CY CY20061101280T patent/CY1105459T1/el unknown
-
2009
- 2009-05-07 US US12/437,226 patent/US20090246172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2350327C2 (ru) | Составы, вызывающие потерю веса | |
| CA2440111A1 (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| JP2005511721A5 (https=) | ||
| JP2004519493A5 (https=) | ||
| JPH0717501B2 (ja) | 高めた無痛覚を与える製薬製品 | |
| Legendre et al. | A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes | |
| AU685741B2 (en) | Sprayable analgesic composition and method of use | |
| Cload | A review of the pharmacokinetics of zidovudine in man | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| AU2018260414A1 (en) | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)ethanone and combinations thereof | |
| KR20040066893A (ko) | 에포틸론을 포함하는 조성물 및 카르시노이드 증후군치료에 있어서 그의 용도 | |
| JP2005513167A5 (https=) | ||
| Chrysant | Experience with terazosin administered in combination with other antihypertensive agents | |
| JP2002505678A (ja) | 腫瘍組織を選択的に制御するための、相乗効果を有する組成物 | |
| JP2008115168A (ja) | 抗アデノウイルス剤 | |
| JPH0296537A (ja) | プロタミンの使用における有害作用の予防または減少用組成物 | |
| CZ79593A3 (en) | Antitussive preparation | |
| KR830008678A (ko) | 진통 조성물 | |
| LT3655B (en) | Medical preparation | |
| RU2163121C1 (ru) | Средство от простуды | |
| Li et al. | Opiate effects on 5-fluorouracil disposition in mice | |
| JP2005525377A (ja) | デスメチルセレジリンの投与による末梢神経障害の予防および処置のための方法 | |
| US20070244102A1 (en) | Combination of Dermaciclane and Opoids as Analgesics | |
| RU2006132127A (ru) | Применение нифуроксазида в качестве компонента комбинированной лекарственной терапии заболеваний, ассоциированных с helicobacter pylori, и способ лечения, направленный на эрадикацию возбудителя | |
| Cunningham et al. | Small cell lung cancer: results of a phase II study of 1, 2, 4 triglycidylurazol |